A Novel Pregelatinized Starch as a Sustained-Release Matrix Excipient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Novel Pregelatinized Starch as a Sustained-Release Matrix Excipient
The authors examine the use of a novel highly functional pregelatinized starch as a controlled-release matrix excipient.


Pharmaceutical Technology



Figure 4
Dissolution study under high mechanical-force conditions. The influence of mechanical force at different rotation speeds on the APAP release rate was investigated. Figure 4 shows dissolution profiles of APAP from HS or HPMC matrix tablets (HS or HPMC/APAP /MCC = 60%/10%/30%). The experiments were performed using a USP Type 1 apparatus at a rotation speed of 100 rpm in a JP-2 buffer containing α-amylase in a 5-g/L concentration. Under these conditions, the release rates of APAP from the HS tablet and the HPMC tablet were almost identical, but the drug-release mechanisms were different. HS matrix tablets were hardly eroded, whereas HPMC matrix tablets gradually became smaller by erosion.


Figure 5
Figure 5 shows the dissolution profiles of APAP of HS or HPMC matrix tablets (HS or HPMC/APAP/MCC = 60%/10%/30%). The experiments were performed using a USP Type 2 apparatus at rotation speeds of 50 or 200 rpm in a JP-2 buffer containing α-amylase in a 5-g/L concentration. Under these conditions, the drug-release profiles of HPMC were remarkably accelerated by increasing rotation speed. On the other hand, those of HS matrix tablets were hardly affected by rotation speed. The difference of 85% APAP release time between 50 and 200 rpm of HPMC and HS were respectively 3.4 h and 0.9 h.


Figure 6
Figure 6 is a schematic description of gelling and drug release of HS and HPMC matrix tablets in dissolution tests. The HS matrix tablets could retain the gel matrix structure with resistance to erosion because the swollen particles of HS did not entirely dissolve and maintain the gel-matrix structure. On the other hand, the HPMC gel layer of the tablet surface was gradually eroded because HPMC particles dissolved completely and could not maintain gel structure. Therefore, the rate of dissolution was accelerated by rapid paddle rotation.


Figure 7
Zero-order release. The effects of PEG on drug-release profiles were investigated to make the formulation of zero-order release matrix tablets. HS or HPMC matrix tablets containing various model drugs (ETZ, APAP, and SSA) with or without PEG, were used in this study.


Table 2
Figure 7 shows the dissolution profiles of model drugs from HS and HPMC matrix tablets. Table II shows the formulations of the tablets. The experiments were performed using a USP Type 1 apparatus at a rotation speed of 100 rpm in a JP-2 buffer containing α-amylase in a 5-g/L concentration. For HS matrix tablets, HS could control the drug-release profiles from first-order to zero-order depending on PEG concentration, regardless of drug solubility. In contrast, HPMC tablets could not provide zero-order release, especially in the case of water-soluble drugs.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here